CXCR3

CXCR3

CXCR3 詳細

Molecule Name
C-X-C motif chemokine receptor 3
分子の別称
CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R, Mig-R, MigR
Drug Development Progress
治験薬の数2
市販薬剤の数0
研究&開発段階Phase 1 Clinical
ターゲットの別称
CKR-L2,G protein-coupled receptor 9,IP-10 receptor,CXCR-3,CXC-R3,CXCR3,C-X-C Motif Chemokine Receptor 3,Interferon-Inducible Protein 10 Receptor,GPR9,C-X-C Chemokine Receptor Type 3,Chemokine Receptor 3,CD183 Antigen,CMKAR3,Chemokine (C-X-C Motif) Receptor 3,Mig Receptor,IP10-R,CD182,CD183,Mig-R,MigR,Receptors, CXCR3
バックグランド
Chemokines are proteins which induce chemotaxis, promote differentiation of immune cells, and cause tissue extravasation. Given these properties, their role in anti-tumor immune response in the cancer environment is of great interest. Although immunotherapy has shown clinical benefit for some cancer patients, other patients do not respond. One of the mechanisms of resistance to checkpoint inhibitors may be chemokine signaling. The CXCL9, -10, -11/CXCR3 axis regulates immune cell migration, differentiation, and activation, leading to tumor suppression (paracrine axis). However, there are some reports that show involvements of this axis in tumor growth and metastasis (autocrine axis). Thus, a better understanding of CXCL9, -10, -11/CXCR3 axis is necessary to develop effective cancer control.

CXCR3 製品リスト

Species
  • Human(3)
  • Mouse(1)
Tag
  • -(3)
  • His Tag & Flag Tag(1)
Host
  • HEK293(4)
Conjugate
  • Unconjugated(3)
  • Biotin-labeled(1)
Grade
  • RUO(4)
Low Endotoxin
  • No(4)
MoleculeCat. No.Product Name種HostStructurePurityActivitySize&Price
CXCR3
Human CXCR3 Protein, Flag,His Tag (Detergent)
Human
HEK293
ELISA

$805.00

20ug
CXCR3
Human CXCR3 Full Length Protein (VLP)
Human
HEK293
HPLC
ELISASPRIdentity

$620.00

20ug
CXCR3
Biotinylated Human CXCR3 Full Length Protein (VLP)
Human
HEK293
ELISA

$620.00

20ug
CXCR3
Mouse CXCR3 Full Length Protein (VLP)
Mouse
HEK293
ELISAIdentity

$620.00

20ug
You Have Viewed 1-4 Of 4 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
OCU-110OCU-10-C-110; OGX-110; OCU-110Phase 1 ClinicalOcugenix Corp
Macular Degeneration
詳細
ACT-777991ACT-777991Phase 1 ClinicalIdorsia Pharmaceuticals Ltd
Diabetes Mellitus, Type 1; Inflammation
詳細
Customer Reviews